pegargiminase + gemcitabine + docetaxel

**Pegargiminase + gemcitabine + docetaxel** is a three-drug combination under clinical investigation as a therapy for various cancers, specifically soft tissue sarcoma and lung cancer. Pegargiminase (also known as ADI-PEG20) is a pegylated bacterial enzyme that depletes arginine, targeting tumors deficient in argininosuccinate synthase 1 (ASS1), commonly making them dependent on extracellular arginine. By depleting arginine, pegargiminase inhibits tumor growth and survival. Gemcitabine is a nucleoside analog that impairs DNA synthesis, while docetaxel is a taxane that interferes with microtubule function, leading to cell cycle arrest. Preclinical data indicates that pegargiminase can enhance the effectiveness of gemcitabine and docetaxel, partly by upregulating transporters and enzymes that promote gemcitabine activity inside tumor cells. Clinical trials (phase I/II) are evaluating safety and efficacy of this combination in soft tissue sarcoma, small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC)[3][5][7].

Other names

ADI-PEG 20 + gemcitabine + docetaxelpegylated arginine deiminase + gemcitabine + docetaxel